Metanalysis shows that Ustekinumab (effective in IBD) may also control skin and joint extra-intestinal manifestations. Despite no effect on spondylitis, UST was effective at PSO, PsA, pyoderma gangrenosum, E nodosum stomatitis and uveitis https://t.co/NPxJdYUM7I